NCT02147015

Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD

Personalized Variable Versus Fixed Dose Corticosteroids Therapy in Hospitalized Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 248 (actual)
• Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The hypothesis is that in acute exacerbated Chronic Obstructive Pulmonary Disease (AECOPD), personalized variable dose glucocorticoid treatment will result in superior clinical outcome when compared to fixed dose therapy.

Detailed description

Treatment with glucocorticoid for acute exacerbations of COPD results in the improvement of clinical outcomes. However, the optimal doses of glucocorticoid for each individual patient has not been determined. According to GOLD Report 2014, a dose of 40 mg prednisone per day for 5 days is recommended (Evidence B), although there are insufficient data to provide firm conclusions concerning the optimal duration of corticosteroid therapy of acute exacerbations of COPD. The purpose of the current study is to compare clinical outcomes of personalized or fixed dose of glucocorticoid in patients with acute exacerbations of COPD.

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

Type	Name	Description
DRUG	Glucocorticoids
DRUG	Antibiotics
DRUG	Inhaled corticosteroid (ICS)
DRUG	Long-Acting Muscarinic Antagonists(LAMA)
DRUG	Short-acting beta2-agonist (SABA)
OTHER	Physical treatments
DRUG	long-acting beta2-agonist (LABA)

Timeline

• Start date: 2014-06-01
• Primary completion: 2017-12-01
• Completion: 2018-04-01
• First posted: 2014-05-26
• Last updated: 2020-10-26

Locations

1 site across 1 country: China